MCRB Valuation

Seres Therapeutics Inc

Add to Watchlist

Advanced Chart

13.860

+1.16(9.134%)1D

MCRB Relative Valuation

MCRB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MCRB is overvalued; if below, it's undervalued.

Historical Valuation

Seres Therapeutics Inc (MCRB) is now in the Fair zone, suggesting that its current forward PS ratio of 13.75 is considered Fairly compared with the five-year average of -6.23. The fair price of Seres Therapeutics Inc (MCRB) is between 3.78 to 16.41 according to relative valuation methord.

Relative Value

Fair Zone

3.78-16.41

Current Price：12.70

Fair

-1.71

Trailing

Forward

0.00

EV/EBITDA

Seres Therapeutics Inc. (MCRB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -6.40. The thresholds are as follows: Strongly Undervalued below -45.03, Undervalued between -45.03 and -25.72, Fairly Valued between 12.91 and -25.72, Overvalued between 12.91 and 32.22, and Strongly Overvalued above 32.22. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.04

EV/EBIT

Seres Therapeutics Inc. (MCRB) has a current EV/EBIT of -2.04. The 5-year average EV/EBIT is -5.27. The thresholds are as follows: Strongly Undervalued below -18.92, Undervalued between -18.92 and -12.10, Fairly Valued between 1.55 and -12.10, Overvalued between 1.55 and 8.38, and Strongly Overvalued above 8.38. The current Forward EV/EBIT of -2.04 falls within the Historic Trend Line -Fairly Valued range.

12.70

Seres Therapeutics Inc. (MCRB) has a current PS of 12.70. The 5-year average PS is 22.73. The thresholds are as follows: Strongly Undervalued below -26.17, Undervalued between -26.17 and -1.72, Fairly Valued between 47.18 and -1.72, Overvalued between 47.18 and 71.62, and Strongly Overvalued above 71.62. The current Forward PS of 12.70 falls within the Historic Trend Line -Fairly Valued range.

-6.29

P/OCF

Seres Therapeutics Inc. (MCRB) has a current P/OCF of -6.29. The 5-year average P/OCF is -3.99. The thresholds are as follows: Strongly Undervalued below -27.85, Undervalued between -27.85 and -15.92, Fairly Valued between 7.94 and -15.92, Overvalued between 7.94 and 19.87, and Strongly Overvalued above 19.87. The current Forward P/OCF of -6.29 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Seres Therapeutics Inc. (MCRB) has a current P/FCF of 0.00. The 5-year average P/FCF is -22.48. The thresholds are as follows: Strongly Undervalued below -126.98, Undervalued between -126.98 and -74.73, Fairly Valued between 29.77 and -74.73, Overvalued between 29.77 and 82.02, and Strongly Overvalued above 82.02. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Seres Therapeutics Inc (MCRB) has a current Price-to-Book (P/B) ratio of 3.65. Compared to its 3-year average P/B ratio of 6.38 , the current P/B ratio is approximately -42.74% higher. Relative to its 5-year average P/B ratio of 7.99, the current P/B ratio is about -54.28% higher. Seres Therapeutics Inc (MCRB) has a Forward Free Cash Flow (FCF) yield of approximately -0.40%. Compared to its 3-year average FCF yield of -73.81%, the current FCF yield is approximately -99.46% lower. Relative to its 5-year average FCF yield of -46.89% , the current FCF yield is about -99.14% lower.

3.37

P/B

Median3y

6.38

Median5y

7.99

-0.20

FCF Yield

Median3y

-73.81

Median5y

-46.89

Competitors Valuation Multiple

The average P/S ratio for MCRB's competitors is 4.09, providing a benchmark for relative valuation. Seres Therapeutics Inc Corp (MCRB) exhibits a P/S ratio of 12.70, which is 210.64% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MCRB.O

Seres Therapeutics Inc

Spero Therapeutics Inc

Anixa Biosciences Inc

Performance Decomposition

Market capitalization of MCRB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MCRB in the past 1 year is driven by Unknown.